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AIM 
To find a molecular marker that would predict the clinical behaviour of 
the local aggressiveness and their metastatic potential. CYCLIN D1 is a 
molecular marker that is over expressed in most of the epithelial cancer .So for 
there are only few studies reporting their significance in penile cancers. From 
our study we tried to correlate their expression with their clinical behavior. 
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CHAPTER   I 
INTRODUCTION AND REVIEW OF LITERATURE 
 
1.1. THE PROBLEM 
Penile cancers are uncommon genitourinary malignancies in the 
western countries. In Europe, the incidence is 0.1-0.9 per 100,000, and in 
the USA, 0.7-0.9 per 100,000. In some areas of Asia, Africa and South 
America, the incidence is significantly higher at 19 per 100.000 1 in these 
countries, penile carcinoma accounts for as many as 10-20% of male 
cancers. This high incidence is related to the poor personal hygiene, 
socioeconomic conditions and the high prevalence of human Papilloma 
viruses. 
In the Madras Metropolitan Tumor registry there were 98 
cases reported between 1999 and 2001 for an average total mid year male 
population of 2,178,842 of which there were 1,643,901 men of 15 – 70 
years age group2. The crude incidence is 1.5per 100,000 population. The 
incidence remains stable in most of the western countries, however there 
is a trend towards a decrease in the incidence in our country due to the 
improvement in the personal hygiene and socioeconomic status. 
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Penile cancers are generally slow growing tumors with predictable 
orderly spread to the superficial and deep inguinal and to the pelvic 
nodes. Distant metastases at presentation are rare. These cancers have a 
spectrum of presentation with indolent slow growing lesions to highly 
aggressive metastatic disease. The survival drops drastically when the 
patient develops nodal metastases3. At present there are few clinical or 
pathological markers which would predict the aggressiveness of these 
tumors. No definite molecular marker has been identified to predict the 
aggressiveness. 
1.2. PATHOLOGY AND PROGNOSTIC MARKERS 
Penile carcinoma essentially metastasizes via the lymphatic system 
and develops mainly through the embolization mechanism instead of 
lymphatic permeation. Distant metastases are very rare and are a result of 
vascular dissemination 2. Spreading essentially develops in stepwise 
fashion; inguinal lymphatic spread occurs first, followed by pelvic 
metastases, and lastly by distant metastases. As a consequence, it is 
extremely rare to observe patients with positive pelvic nodes or distant 
metastasis without inguinal lymph-node involvement. The primary tumor 
is localized to the glans in 48% of cases, prepuce in 21%, both glans and 
prepuce in 9%, coronal sulcus in 6%, and less than 2% in the shaft 5. 
Palpable inguinal nodes are present at   diagnosis in 58% of patients 
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(range 20-96%) 6. Of these patients, 17-45% has nodal metastases, while 
the remaining patients have inflammatory disease secondary to an 
infection of the primary tumor. 
The histological types, grade and growth patterns of penile cancers are 
TYPES OF SCC 
• Classic 
• Basaloid 
• Verrucous and its varieties (24): 
• Warty (condylomatous) carcinoma 
• Verrucous carcinoma 
• Papillary carcinoma 
• Hybrid verrucous carcinoma 
• Mixed carcinomas (warty-basaloid carcinoma, adeno-basaloid  
            carcinoma) 
• Sarcomatoid 
• Adenosquamous 
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GROWTH PATTERNS OF SCC 
• Superficial spread 
• Nodular or vertical-phase growth 
• Verrucous 
 
DIFFERENTIATION GRADING SYSTEMS FOR SCC 
 
• Broders system  traditionally used as a grading system 
• Maiche system score7 currently seems to be the most suitable      
 grading system 
Of all the cancers, squamous cell carcinomas account for more than 
95%. The prognostic factors are the T status, the histological grade, and 
the presence of the nodal metastasis. The histological grade predicts the 
development of the inguinal metastases to some extent. However 
substantial number of patients with high grade N 0 disease undergoing 
nodal dissection will have pathological N0 disease facing the morbidity of 
inguinal dissection. 
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1.3. CLINICAL STAGING 
AJCC 2002   TNM TUMOUR STAGING 
T - Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Ta Non-invasive verrucous carcinoma 
T1 Tumour invades subepithelial connective tissue 
T2 Tumour invades corpus spongiosum or cavernosum 
T3 Tumour invades urethra or prostate 
T4 Tumour invades other adjacent structures 
N - Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No evidence of lymph node metastasis 
N1 Metastasis in a single inguinal lymph node 
N2 Metastasis in multiple or bilateral superficial lymph nodes 
N3 Metastasis in deep inguinal or pelvic lymph nodes, unilateral or 
bilateral 
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M - Distant metastasis 
MX Distant metastases cannot be assessed 
M0 No evidence of distant metastases 
M1 Distant metastases 
 
1.4 SURVIVAL 
 
An overall 5-year survival rate of 52% has been reported. This 
ranges from 66% in patients with negative lymph nodes to 27% in 
patients with positive nodes 8, 9 and 0-38.4% in patients with pelvic node 
involvement. Most patients are elderly and the neoplasm has a slow 
growth rate. Death from cancer is usually a consequence of local 
complications, such as infection, haemorrhage of the ulcerated tumour or 
ulcerated inguinal metastases. The crude 5-year survival rate was 95% for 
patients with negative nodes, 76% when only inguinal nodes were 
positive, and 0% when the pelvic nodes were positive. The adverse 
prognostic factors were (1) involvement of > 3 inguinal nodes, (2) 
perinodal infiltration in the inguinal area, and (3) pelvic node 
involvement.10 
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CHAPTER   II 
MOLECULAR ASPECTS OF CELL CYCLE - THE ROLE  
OF CYCLIN D1 
 
2.1 CELL CYCLE 
Cell cycle is comprised of four   phases:  g1, s phase, g2 and m 
phase. 
The g1 phase before the mitosis are the times of regulatory decisions of 
the cycle.(fig 1) 
2.2 CYCLIN DEPENDENT KINASES  
The major transitions of the eukaryotic cell cycle is triggered by a 
family of serine threonine  kinases called cyclin   dependent  kinases (  
cdk ) at least nine cdks  are known so far 11. CDK activation requires the 
regulatory subunits called the cyclins and phosphorylation of a conserved 
threonine  by the  cdk  activating kinase ( CAK ) which itself is a 
complex of a regulatory   cyclin H and a catalytic cdk7 subunit , cellular 
cdk levels tend to  remain in constant excess through out the normal cycle 
and catalytic subunit of cdks are regulated post translationally. Cdk are 
closely related in size and sequence (> 40 % identity).  
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In humans, the growing list of cdks include the confounding 
member, cdc2 and cdk2- cdk7. Our understanding of cdk structure and 
function (fig-1) is based largely on studies of  prototypical cdks of 
s,pombe( cdc2 ), s. Cerevisiae ( cdc28)  and  vertebrates ( cdc 2  and cdk 
2 ) .  The typical   cdk  catalytic unit  
                                            Fig 1 
 
contains 300 aminoacids. The catalytic subunit is completely in active 
when it is monomeric and unphosphorylated. Cyclins are the primary 
regulators of the cdks. 
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p34 CDC 2 (cdk1) 
The earliest reported members of the cdk family constitute 
homologous 34 kda products encoded by the yeast cell division cycle 
(cdc) genes.  p34 cdc2 (cdk1) is a highly conserved cyclin associated 34 
kda protein kinase that becomes activated on phosphorylation. 
Complexed with cyclin b it forms the maturation factor (MPF).Without 
p34cdc2 the cells are unable to divide12. p34 cdc2 distribution is 
cytoplasmic during the interphase, shifts into the nucleus at the beginning 
of the prophase and extends through the cell in the mitiotic phase, as the 
key regulators of the cycle, the cyclin dependent kinases must be tightly 
regulated by extra and intra cellular signals. The activity of cyclin 
dependent kinases is controlled by four highly conserved biochemical 
mechanisms forming a web of regulatory pathways unmatched in this 
elegance and intricacy. 
2.3 CELL CYCLINS 
Cyclins are a class of structurally related proteins that bind and 
activate the catalytic subunit of the CDKs. To data there are   eight types 
of cyclins, (Cyclins A – H )  and all of them share an ∼ 150 amino acids 
of the region of homology called the cyclin box which is responsible for 
the CDK binding and activating14. Cyclins can be roughly divided into 
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two subfamilies: the G1 cyclins and the mitotic cyclins. The G1 Cyclins 
(C, D, E) are short lived and have rapid turnover throughout cell cycle( 
fig 2). Their levels are determined of    transcription of their m RNA. The 
mitotic cyclins ( A,B) are very stable throughout the interphase but 
undergo rapid proteolysis by an ubiquitin dependent pathway during 
mitosis. Compared to the mitotic cyclins, the G1 cyclins have a longer C 
terminal sequence after the cyclin box, and it is this part of the protein 
that seems to confer instability to the G 1 cyclins 14. The function of 
cyclins is primarily controlled by changes in the cyclin levels which 
increase at specific stages and are often categorized by the stage at which 
they are expressed. The G 1 cyclins  differ from the mitotic cyclins in 
their overall primary structure  and this has implications for their stability 
during the cell cycle. The transcription of the mitotic cyclins, Cyclin A 
and B are cell cycle dependent and their levels are determined both by 
transcription and proteolysis15. Protein degradation is an effective method 
for promoting unidirectional cell cycle transitions because of its rapidity 
and irreversibility. Three major cell cycle transitions, entry into S phase, 
separation of sister chromatids and exit from mitosis, require the 
degradation of specific proteins via the ubiquitination by 26S proteosome 
pathway. 
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The degradation of mitotic cyclins involves the ubiquitin 
dependent proteolytic machinery and a small sequence motif called the 
Destruction box located at the N terminus. This region has a small cluster 
of conserved residues followed by a lysine rich stretch. The destruction 
box region differs between Cyclin A and B and probably accounts for the 
finding that in mitosis Cyclin A is degraded before Cyclin B. G1 cyclins 
lack the mitotic destruction box but contains the PEST sequences as the 
peptide motifs that are important for proteolysis. PEST sequences (rich in 
proline, glutamic acid, serine, and threonine) are frequently present in 
unstable proteins such as G1 cyclins and contain specific sites of 
phosphorylation. Phosphorylation of PEST regions facilitates the 
destructions of PEST sequence proteins. It is not the PEST sequences per 
se but the specific motifs within them that actually control the PEST 
sequence recognition by the ubiquitination machinery 16. 
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Cyclins are thought to target the CDK to specific substrate and 
subcellular locations. Cyclin expression varies during cell cycle and the 
periodic expression of different cyclins defines the start of each phase of 
the cell cycle and also marks the transitions between the various phases. 
Cyclins and their cognate CDK catalytic subunits non covalently form 1:1 
complexes to produce the CDK holoenzyme. Specific CDKs operate in 
distinct phases of cell cycle. At least two stages within cell cycle are 
regulated in response to the DNA damage, the G1 – S and the G2 –M 
transitions. These transitions are called CHECK POINTS at which the 
cells delay cell cycle progress to allow repair of the DNA damage. Check 
points are thought to consist of surveillance mechanisms that can detect 
DNA damage, signal transduction pathways that transmit and amplify the 
signal to the replication or segregation machinery and possibly repair 
activities 17.The timing of all the events that transpire during the cell cycle 
are controlled , through protein phosphorylation. 
 16
Table 1 :-   Cyclins and cell cycle phases. 
S. No Cyclin Cell Cycle Phase 
1 CYCLIN D1 EARLY G1 phase 
2 CYCLIN E G1 / S PHASE TRANSITION 
3 CYCLIN A S PHASE 
4 CYCLIN B G2  / M PHASE 
 
2.4 CYCLIN D 
The first groups of cyclins that are expressed after the cells are 
stimulated to enter the cell cycle are the D cyclins. D type cyclins act as 
growth factor sensors. Cyclin D has a relatively short half life of 20 min. 
approximately and rapidly disappears with the removal of mitogenic 
stimuli or the addition of antiproliferative agents.18  Cyclin D complexed 
with respective partners CDK4 and CDK6, participates in the 
transduction of external signals (mitogenic or proliferative) to other 
components of G1 / S transition cell machinery. Cyclin D helps in 
moving G0 cells into G1 And early G1 Cells into the G1 /S transition in 
response to the extra cellular stimuli. The D type cyclin belongs to a 
distinct subset within cyclin family based on structural and functional 
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criteria. There are three genes identified under this family, Cyclin D1, D2 
and D3 19. 
Table 2  Gene Locations Of Cyclins 
GENE CHROMOSOME LOCATION RNA PROTEIN 
CCD1 
(CYCLIND1) 
11q13 4.5 KB 295AA 
CCD2 
(CYCLIN D2) 
12p13 7KB 289AA 
CCD3 
(CYCLIN D3) 
6p21 2.2KB 292AA 
 
The chromosome 11q13 has been identified as a site of tumor 
specific translocations .In the parathyroid adenomas, due to clonal 
inversion, the cyclin D1 gene on chromosome 11q13 is juxta posed on 
chromosome 11q15. This results in an increase in Cyclin D1 expression. 
20,21 Frequent rearrangements of 11q13 has been noted in B cell 
lymphomas and multiple myelomas. The same locus is subjected to 
translocation22, retro viral insertion, gene amplification by yet poorly 
defined mechanisms in lymphomas, squamous cell carcinomas and breast 
carcinomas implying that Cyclin D1 acts as a Oncogene –positive   
growth regulator. 
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2.5 CYCLIN D1 GENE 
The cyclin D1 gene (CCND1), linked closely to the bcl-1 gene on 
chromosome 11q13, is sometimes referred to as the PRAD1 gene because 
of an initial finding of frequent rearrangement of this gene in benign 
parathyroid adenomas.49 The important role of cyclin D1 in parathyroid 
neoplasia has subsequently been confirmed50.  The bcl-1 locus, so called 
because of the involvement of this chromosomal region in translocations 
{(t11; 14) (q13, q32)} characteristic of certain B cell lymphomas (now 
called mantle cell lymphomas), was originally thought to be identical to 
the cyclinD1/PRAD1 gene, but it has been shown to reside 110–130 kb 
upstream or centromeric to the PRAD1 gene51. However, no 
transcriptional units have been identified in the immediate vicinity of the 
major translocation cluster (MTC) 52 of the bcl-1 breakpoint area or any 
of the breakpoints that have been found up to 63 kb telomeric to the MTC 
region53. The absence of CpG islands between the original bcl-1 locus 
and PRAD1’s CpG Island 51 52 54 lends further support to the notion that 
no other gene lies within this interval. Thus, the probability remains that 
the cyclin D1 / PRAD1 gene is the bcl-1 Oncogene. Although bcl-1 often 
co-amplifies with other genes on 11q13 (such as EMS-1, FGF3, FGF4, 
int-2, and hst-1), cyclin D1 and EMS-1 are the only proteins, so far, over 
expressed as a result. 52 55 56 
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Fig 3 
 
 
 
 
 20
The D type cyclins contains the sequence LEU-X- Cys - Glu near 
their aminoterminus (fig3). This sequence is common to DNA vital 
oncoproteins SV40 T antigen, adenovirus E1A and human Papilloma 
virus E7 that bind and activate pRB and pRB  related proteins.  The D 
type Cyclins bind directly to pRB and p107 invitro and the interactions 
are disrupted by point mutations of the LEU-X- Cys - Glu motif. The 
Oncogene derived peptides that contain this motif compete with Cyclin d 
to bind to pRB23. Cyclin D2 and D3 form more stable complexes than 
cyclin d1 suggestive of differences in functional interactions not being 
equivalent24. The functional interaction of Cyclin D with pRB 
underscores its role as a positive growth regulator with Oncogenic 
potential. 
2.6 CELL CYCLE IN NEOPLASIA 
Predictably, proteins involved in driving the cell cycle, such as 
cyclins, are frequently over expressed in primary tumors, whereas 
proteins that slow cell division, such as the CKIs, are often inactivated. 
Of the many cell cycle regulators implicated in the development of 
cancers, cyclin D1 is among the most prevalent. Over expression of D-
type cyclins has been shown to contract the G1 phase, decrease cell size, 
and reduce the dependency of the cell on mitogens 25-27 in animal models 
and cell lines. 
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A link between D-type cyclins and the retinoblastoma protein 
The connection between D-type cyclins and tumorigenisis is 
bolstered further by compelling evidence that D-type cyclins are 
important in cell cycle regulation of the retinoblastoma tumor suppressor 
protein (pRB), an approximately  105 kDa nuclear phosphoprotein.28-
30.The amount of pRB is not altered with progression of the cell cycle, 
however, the phosphorylation  state of pRB is cell cycle dependent31-33  . 
pRB is hypophosphorylated throughout G1 phase, phosphorylated just 
before S phase, and remains phosphorylated  until late mitosis. 
Hypophosphorylated pRB arrests cells in G1,34an effect most likely 
mediated through complex formation with DNA binding proteins 
(including members of theE2F family)35-37 required for transcriptional 
activation of cellular genes. Phosphorylation of pRB during late G1 phase 
reverses the growth suppressive effects of pRB, by untethering E2F from 
its inhibitory constraint and thereby allowing the activation of genes 
required for DNA replication.38Because D-type cyclins are able to bind to 
pRB through an N-terminal LXCXE motif, 23,39,40they are excellent 
candidates for G1 phase pRB protein kinases as part of a complex with 
their specific Cdk partners. Interestingly, this LXCXE motif is common 
to the SV40 T antigen, adenovirus E1A, and human Papilloma virus E7 
proteins,38whichmay also bind to pRB and release E2F; a fact that in part 
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explains the oncogenic potential of these viruses. Support for the idea that 
D-type cyclins can inactivate pRB comes from reports that increased 
amounts of D-type cyclins can reverse the pRB induced cell cycle arrest 
and accelerate progression through G127 39 41 42. 
Cells that lack functional pRB have significantly lower levels of 
Cyclin D1 and Cyclin D1 – CDK 43-46 a result which has been interpreted 
to mean that hypophosphorylated pRB is involved in the stimulation of 
Cyclin D1 transcription. The reported ability of exogenously expressed 
pRB to induce cyclin D1 is in concordance with this hypothesis .47 Thus a 
negative feed back loop seems to exist in which Cyclin D1 synthesis and 
activation lead to pRB phosphorylation , which in turn causes decreased 
Cyclin D1 expression. 48 
2.7 CYCLIN D1 EXPRESSION IN HUMAN CANCERS 
In addition to parathyroid adenomas, increased cyclin D1 
expression has been shown in a number of primary human tumors and 
cell lines. In general, primary tumors provide more reliable information 
as it is often difficult to determine when the amplification occurred 
during the development of the cell line. This is because other influences, 
which cause the cells to proliferate at faster rates, may up regulate cyclin 
D1 expression. Although increased cyclin D1 protein expression 
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correlates in most instances with amplification of the CCND1 gene, this 
is not always the case. In some tumors there is a increased cyclin D1 
RNA and/or protein without apparent gene amplification, suggesting that 
other cellular genes (such as the retinoblastoma gene) may impact on the 
protein expression of cyclin D1,57 although all the mechanisms have not 
yet been satisfactorily elucidated. DNA amplification is the most frequent 
abnormality affecting the CCND1 gene. Furthermore, no major 
abnormality in the coding region of the cyclin D1 gene has been detected 
58,59 suggesting that it is the normal gene product that contributes to 
tumorigenesis. 
BREAST CANCERS 
About half of all invasive breast cancers 76-79 have raised 
expression of cyclin D1 compared with normal epithelium, although the 
figure for gene amplification averages around 13%. 57 Some earlier 
studies80-83 failed to find any significant association between 11q13 
amplification and oestrogen receptor positive cancers, but a number of 
materials 84–93 has now accumulated supporting a correlation between 
cyclin D1 gene amplification and protein over expression with oestrogen 
receptor positive tumors. Studies in mice 94 95 and man 96 link cyclin D1 to 
steroid induced proliferation of mammary epithelial cells. In fact, cyclin 
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D1 appears to be an independent activator of the oestrogen receptor. 97 
Despite the correlation with oestrogen receptor status, there is lack of 
agreement as to the prognostic significance of cyclin D1 in breast cancers 
in general. More work need to be done to identify the subsets of patients 
in whom cyclin D1 may play a more prominent role. It seems that cyclin 
D1 is more important in node positive,74 well differentiated, and 
particularly lobular, varieties than other types of invasive breast cancer.91- 
93The role of cyclin D1 in ductal carcinoma in situ (DCIS) 98, high grade 
lesions 99 were more likely to show gene amplification but demonstrated 
lower percentages of nuclei expressing cyclin D1 protein than low grade 
lesions, which suggests that mechanisms other than gene amplification 
may be responsible for increased cyclin D1 protein. In this situation, 
assessment of cyclin D1 protein in combination with pRB may provide 
more useful information.100-102  The  over  expression of cyclin D  mRNA, 
determined by in situ hybridization, was able to distinguish DCIS from 
atypical ductal hyperplasia and other lesions associated with a low risk of 
progression to invasive carcinoma103. 
In patients with ER-positive tumors, high levels of cyclin D1 
mRNA were associated with increased risk of relapse, local recurrence, 
metastasis, and death. There were no clinical correlations with cyclin D1 
expression in ER-negative disease. In patients who received endocrine 
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therapy for their primary or recurrent breast cancers, there was an 
apparent association between a high cyclin D1 mRNA level and shorter 
response duration within the ER-positive subgroup. These findings 
indicate that over expression of cyclin D1 mRNA correlates with a worse 
prognosis within the ER-positive breast cancer phenotype and may be a 
contributing factor to the development of endocrine resistance in ER-
positive disease104. 
CYCLIN D1 IN PANCREATIC TUMORS 
Overexpression of cyclin D1 was identified in 43% of cases, and no 
correlation was observed with clinical phenotype. The novel observation 
of frequent over expression of cyclin D1 suggests that this established 
Oncogene might be implicated in the pathogenesis of human Pancreatic 
Endocrine Tumors. The absence of detectable alterations in cyclin D1 
genomic structure suggests that the mechanism for its Oncogenic 
activation in PETs may be transcriptional or posttranscriptional105. 
HEAD AND NECK SQUAMOUS CELL CARCINOMAS 
A range of 35% to 64% of head and neck squamous carcinomas 106-
111 (squamous carcinomas in the oral cavity, nasopharynx, pharynx, 
hypopharynx, and larynx) show over expression of cyclin D1 and/or 
CCND1 amplification. Over expression of cyclin D1 in the initial surgical   
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specimens   corresponds not only with more  frequent recurrence 109 but 
also with more advanced disease, lymph node involvement, and reduced 
overall survival. 107  110 In one study of squamous carcinomas of the 
larynx, a correlation among cyclin D1 gene amplification, mRNA over 
expression, and tumor progression, was shown in a cohort of 46 patients. 
107 The above and another study 110demonstrated a significant association 
between molecular abnormalities of the cyclin D1 gene and pathological 
measures of poor prognosis. Recently, over expression of cyclin D1 
protein in resected material from head and neck squamous carcinomas 
was found to be an independent prognostic factor 111 a finding that has 
been confirmed. 112 In Japanese hypopharyngeal squamous cell 
carcinomas, cyclin D1 gene amplification and protein over expression 
correlated not only with prognosis but were also useful in identifying 
optimum treatment regimens. 113 Cyclin D1 negative tumors responded 
particularly well to multimodality treatment in these tumors. 
ESOPHAGEAL CANCERS 
In approximately 30% of esophageal cancers, amplification 113 and 
over expression 114–116 of cyclin D1 have been demonstrated, with several 
studies showing an association with increased mortality. 116–118 Also, the 
ability of antisense to cyclin D1 to reverse the transformed phenotype of 
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esophageal cancer cells 119 provides strong supporting evidence for the 
molecule’s role in cancers at this site. 
Cyclin D1 mRNA was overexpressed in the cytoplasm of cancer 
cells that showed cyclin D1 gene amplification by Southern blot 
hybridization. Cyclin D1 antigen was overexpressed in the nucleus of 
these cancer cells. The distribution of cyclin D1 mRNA-positive cells was 
similar to that of cyclin D1 antigen-positive cells in the cancer tissues. 
The overall 5-year survival of patients with strongly staining tumors was 
significantly lower than that of patients with weakly or non staining 
tumors (7 versus 59%; P < 0.01). There was no significant correlation 
between cyclin D1 expression and other clinic pathological factors. These 
results suggest that cyclin D1 may play an important role in 
carcinogenesis and that cyclin D1 over expression may be a useful 
prognostic factor in esophageal cancer120. 
HEPATOCELLULAR CARCINOMAS 
Amplification and raised protein concentrations have been 
observed in 10% of hepatocellular carcinomas. 121, 122 Among other 
hypothesis, it has been suggested that hepatitis B or C viral integration 
within the cyclin D1 gene or one of its adjacent regulator sequences may 
be a mechanism in malignant transformation. 123 In some reports 124 125 the 
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hepatitis B viral genome was detected on chromosome 13 at an upstream 
site close to the CCND1 gene. Another study122 showed that cyclin D1 
amplification was restricted to hepatocellular carcinomas that contained 
the hepatitis B or C virus. Although the evidence is scant, the possibility 
of an interaction between these viruses and cyclin D1 is an intriguing one. 
COLORECTAL CANCERS 
Initial reports 126 using cell lines suggested that cyclin D1 was 
not an important factor in colorectal adenocarcinomas, recent work has 
shown not only does cyclin D1 over expression occur as an early event in 
tumor progression, it may also be an independent prognostic factor.127 
There is increased nuclear immunostaining in adenomatous polyps and 
adenocarcinomas, but not in adjacent normal, transitional or hyperplastic 
mucosa. These findings apply to both sporadic 128 and familial forms 129 of 
colon cancer. Furthermore, as has been demonstrated in the oesophagus, 
antisense to cyclin D1 inhibits the growth and tumorigenicity of colon 
cancer cells. 
GENITOURINARY CANCERS 
Amplification of 11q13 has been demonstrated in between 6% and 21% 
130–132 of transitional cell cancers of the urinary bladder, although nuclear 
accumulation of the protein appears in a much greater percentage of 
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cases. Alterations in cyclin D1 appear to be an early event in 
tumorigenesis of the urinary bladder, but the prognostic significance of 
amplification and over expression remain to be determined. In one study 
a significant relation between cyclin D1 over expression and low tumor 
grade as well as T classification were observed, 133 these findings were 
not found in another study. 134 Abnormalities of cyclin D1 are also 
common in both vulval and cervical squamous cell carcinomas. 135 At 
these sites, cyclin D1 appears to inactivate pRB in a similar manner to 
oncogenic human Papilloma virus genotypes. Thus, it seems that in 
vulval and cervical squamous carcinomas, human papilloma virus 
proteins can circumvent cellular requirements for cyclin D1 136 or vice 
versa. In endometrial carcinomas, 11q13 amplification is exceedingly 
rare, but about 40% of cases show aberrant accumulation of cyclin D1. 137 
Again, the effect of other genes is the likely explanation for this 
phenomenon, al-though in this case the interaction of cyclin D1 with p53 
138 appears to be more important than with pRB. Because cyclin D1 can 
activate the oestrogen receptor independently, 98 if this molecule were 
also over expressed in endometrial hyperplasia it would provide a useful 
link with known pathogenetic mechanisms. In epithelial ovarian cancers, 
abnormalities of cyclin D1 are early events in the progression to 
malignancy, and they may be associated with the degree of 
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transformation.139There is a strong positive correlation between cyclin D1 
and c-K ras  immunoexpression, 140 but no correlation with the c-erb-B2 
oncogene. 141 The relation with the Ras proto-oncogene is important 
because it has been shown that inactivation of Ras in cycling cells causes 
a decline in cyclin D1 protein, accumulation of the hypophosphorylated, 
growth suppressive form of pRB, and G1 arrest. 142 143 Strangely, the 
relation between cyclin D1 amplification and oestrogen is not as clear cut 
as has been demonstrated in the breast.  141 
LUNG CANCERS 
Studies have shown a higher frequency of bcl-1 gene 
amplification in squamous cell carcinomas of the lung than in other types 
of non-small cell lung cancer, 145 and an association with poor grade and 
high Ki-67 labelling index. 146However, current research is contradictory 
as to the prognostic usefulness of detecting cyclin D1 protein over 
expression. 147–148 From studies of the resection margin epithelia of lung 
cancer patients, com-pared with non-smoking controls, it seems that 
genetic alteration of cyclin D1 is an early event in non-small cell lung 
cancer, 148 and therefore an attractive therapeutic target. 
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SKIN CANCERS 
Compared to normal skin and benign lesions, cyclin D1 protein 
expression is significantly greater in various malignant skin tumors, 
including squamous cell carcinomas, melanomas, and malignant fibrous 
histiocytomas. 149 Studies of chemically induced squamous cell 
carcinomas in mice also implicate cyclin D1 (and other G1 cyclins) in the 
process of carcinogenesis. 150 
SARCOMAS 
Amplification of the cyclin D1 gene has been  detected in a small 
percentage of a variety of sarcomas, 151 but the increased cyclin D1 
protein expression in at least some cases may due to a mutant protein 
with greater stability. 152 
MANTLE CELL LYMPHOMAS 
All or almost all mantle cell (centrocytic) lymphomas in 
several studies51 60–67 have raised activity of cyclin D1, even in cases in 
which no rearrangement at 11q13 was found. 68 Generally, however, 
positive nuclear staining with monoclonal antibody to the cyclin D1 
protein correlates with amplification of the CCND1 gene as well as 
mRNA. 69 It has been suggested that expression of cyclin D1 by 
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lymphocytes in the mantle zone impairs the capacity of these cells to exit 
the cell cycle and to differentiate into mature plasma cells. 70 This 
pathogenetic theory is contradicted by a recent finding of cyclin D1 
protein expression in 26% of plasma cell neoplasms, however, the same 
study 71 supports a relation between mantle cells, plasma cells, and their 
corresponding neoplasm. An international lymphoma consensus 
72acknowledged the importance of chromosome 11q13 translocation and 
increased cyclin D1 expression in mantle cell lymphomas; in the future it 
may be elevated to a defining characteristic, given the high sensitivity and 
relative specificity of this molecule in mantle cell lymphoma compared 
with other B cell neoplasms. 61 73 Cyclin D1 protein expression and bcl-1 
gene rearrangement has been identified as a key component in the 
diagnosis of the blastoid variant 74 of mantle cell lymphoma as well as in 
an entity closely related to mantle cell lymphoma multiple lymphomatous 
polyposis.75 
OTHER SITES AND MALIGNANCIES 
Central nervous system malignancies such as astrocytomas 153 
and  glioblastomas 154 are not exempt from cyclin D1 amplification or 
protein over expression, nor are gastric adeno-carcinomas,155 156 
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pancreatic adenocarcinomas  (may be associated with a poor prognosis), 
157or squamous carcinomas of the gall bladder. 158 
Only a few human tumors are still holding out against the storm of 
cyclin D1 research. These include pituitary tumours,159 renal cell tumors, 
prostate carcinoma, 160 and many haemopoietic malignancies. However, 
with some of these tumors there are possible links with cyclin D1. For 
example, the 11q13 region (although apparently not the CCND1 gene) is 
important in pituitary neoplasms of MEN-1, and cyclins including cyclin 
D1 are important in renal development. 
In addition to the MEN1 tumor suppressor gene, the cyclin D1 
oncogene has demonstrated a role in the pathogenesis of parathyroid and 
gastroenteropancreatic neuroendocrine tumors. Upregulation of cyclin D1 
is observed early in tumor formation, implying a possible role in tumor 
initiation. Overexpression of cyclin D1 in the parathyroid glands of mice 
resulted in the tandem regulation of cellular proliferation and hormonal 
secretion, a feature intrinsic to neuroendocrine tumors.161 
Cyclin D1 (CCND1) is a key cell cycle regulatory protein, the 
over expression of which is often found in human tumors and is 
associated with cell proliferation and poor prognosis. A common adenine-
to-guanine substitution polymorphism (A870G) in the CCND1 gene 
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results in an altered messenger RNA transcript and a longer-life protein, 
which are preferentially encoded by the A allele. The CCND1 870A allele 
may be associated with colorectal cancer, and particularly with forms of 
the disease that result in severe morbidity and mortality162. 
2.8 CYCLIND1 AND MOLECULAR ALTERATIONS IN 
PENILE   CANCER 
Alterations pointing to a disturbed p16 INK4A /cyclin D1/Rb 
pathway are commonly present in penile carcinomas144. Activity of high-
risk HPV and the resulting increase in p16 INK4A expression was the 
most frequently detected mechanism amongst the mechanisms that were 
analyzed, followed by p16 INK4A hypermethylation and BMI-1 over 
expression. In addition, there is evidence that penile carcinomas being 
etiologically heterogeneous, with only a proportion of cases attributable 
to HPV infection. These results are important when HPV-based 
immunotherapeutic interventions are envisaged, because in contrast to 
patients with cervical carcinoma, only about 26% of patients with penile 
carcinoma are likely to benefit from these vaccines. 
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CHAPTER III 
MATERIALS AND METHODS 
Penile cancer patients reported to our institute  between the year 
1998 and 1999 who were accepted for treatment were chosen for analysis. 
The data were collected from the case records of the Tumor registry 
.There were 104 cases of carcinoma penis that were accepted for 
treatment in our institute between the year1998 and 1999. These records 
were analyzed. 
3.1 PATIENT SELECTION 
 Of the 104 cases who were accepted for treatment at our institute, 
those patients who  had not    completed the treatment were excluded 
from the study. Those who lost to follow up and histology other than 
squamous were also excluded from the study.Of those records, 
37squamous cell carcinoma patientsof different grades were chosen .The 
inclusion criteria  are – completed treatment , regular follow up , 
squamous cell carcinoma any grade , complete pathology is available  
with the paraffin blocks . 
3.2 DATA COLLECTION 
Case records of those patients who fulfilled the above criteria were 
taken for analysis. The relevant data were taken from the case records and 
entered into the database for analysis. 
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3.3 SAMPLE COLLECTION 
The pathology reports of these patients included for analysis were 
taken and their corresponding paraffin block numbers were taken. These 
blocks are then retrieved from the pathology department paraffin block 
bank. Five micron sections are taken from the paraffin blocks and 
incubated overnight. Suitable positive and negative controls are also 
taken simultaneously from the previously Cyclin D1 positive sections 
from the laryngeal cancer .After overnight Incubation the slides were 
submitted foe immunocytochemistry with Cyclin D1. 
  3.4  IMMUNOCYTOCHEMISTRY 
The paraffin embedded sections of 5 µ were placed on the APES 
coated slides.The slides were treated in Xylene consecutively twice for 8 
minutes each for dewaxing the sections. This was followed by treatment 
in 100% alcohol consecutively twice for dehydration. The slides were 
then washed in tap water for 8- 10 minutes, taking care not to disturb the 
tissue sections . Followed by tap water wash , the slides were then place 
in 0.3% hydrogen peroxide for 30 minutes to quench the endogenous 
peroxidase activity in the tissues . 
3.5  ANTIGEN RETRIEVAL 
Antigen retrieval is needed in the study in order to expose the 
epitopes  for immune reaction .Antigen retrieval was done using10 mM 
Citrate buffer using  , with wet autoclaving at 121° C in 10mM Citrate 
buffer pH6. After antigen retrieval the slides were cooled and washed 
with phosphate buffered saline for 5 min. 
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3.6  BLOCKING AND ANTIBODY REACTIONS 
The slides were arranged on a moist chamber, to prevent drying of 
the sections and 100 µ of 2% Bovine Serum Albumin (BSA) was added 
to each section, taking care to cover the whole section and left 
undisturbed for 30 min. Following gentle tipping of BSA off the slides , 
the primary antibody ( 75 µl )  in 1: 100 dilutions was added to each 
sections .Care was taken to omit the negative control. The slides were left 
overnight undisturbed to incubate the primary antibody. 
The slides were washed with PBS thrice for 5 minutes each to 
wash off the excess of primary antibody and secondary antibody (75 µl ) 
was added  to each slide and incubated for 35 minutes. The slides were 
washed in PBS thrice for 5 minutes each followed by addition of ABC 
(Avidin – Biotin Complex -75µl) onto each slide and incubated for 30 
minutes. 
3.7 TREATMENT WITH CHROMOGEN DI- 
AMINOBENZEDENE 
The slides were washed in PBS thrice for 5 minutes each to wash 
excess of ABC and the slides were treated in a solution of DAB ( 150 ml 
of water + 150 ml PBS+100 µl hydrogen peroxide + 150 mg of DAB) for 
5 minutes . The excess DAB was washed off the slides in tap water for 5- 
10 minutes and counterstained in haematoxylin for 2 minutes. 
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CHAPTER IV 
ANALYSIS 
The stained slides were the scored by the pathologist. Only the 
nuclear staining was considered as positive. All cytoplasmic and other 
nonspecific staining were not considered as positive. Since the adjoining 
normal squamous epithelium did not over express Cyclin D1 and the 
corresponding squamous epithelium of the cervix , were > 5 % of 
expression is considered positive , the same principle was applied here . 
Depending on the staining intensity, the same is scored as +, ++, +++. 
The age distribution were  
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RESULTS 
Of the 37 cases analyzed and studied the T status distribution were :- 
T status Numbers Percentage 
1 6 16.2% 
2 21 56.8% 
3 9 24.3% 
4 1 2.7% 
Total 37 100% 
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The N status were 
N Numbers Percentage 
0 30 81.1% 
1 1 2.7% 
2 6 16.2% 
 
 
The grade distribution were 
 
Grade Numbers Percentage 
1 16 43.2% 
2 12 32.4% 
3 9 24.3% 
 
Of these  37 cases that were followed up , there were 2 local 
recurrences (5.4%) that were salvaged and 10 regional recurrences(27%)  
. The cyclin D1 expression pattern in all  cases were analyzed . Cyclin D1 
expression pattern with respect to the T status showed 14.3 % of T 2, 44.4 
% of T3  tumors expressed Cyclin D1 .None of the T1 or T4 tumors 
expressed .applying Chi square test did not show any statistical 
significance ( p value   0.1244 ). 
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Cyclin D1 expression pattern with respect to grade of the tumor 
showed 41.7 % of grade II tumors and 22.2 % of grade III  tumors 
overexpressed Cyclin D1 which was found to statistically significant ( p 
value 0.0197)  Even though the recurrence pattern and the Cyclin D1 
correlation  showed  Cyclin  D1 over expression only in 18.9% which  
statistically not significant ( p =0.270 ) there was trend towards increased 
recurrence in those tumors that were over expressing Cyclin D1. 
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DISCUSSION 
       Cyclin D1 is one of the molecular markers that is over expressed in 
the actively dividing malignant epithelial cells. Most of the epithelial 
cancers as described before, over express Cyclin D1 .However there are 
only very few studies done to know the significance of   this over 
expression in  penile cancers. In our study we attempted to find the 
significance of this over expression with respect other clinico 
pathological factors.  
               In our study the cases chosen are highly selected with the 
criteria which was described above. Even though this may result in 
selection bias , the complete details are available only for those chosen 
cases .  
                Search of literature didn’t show any  reports regarding the cut 
off values for the scoring system of the expression.  However   there    
reports using  > 5% of the stained cells as positive in cervical cancers. 
Using the same principle, our slides were scored .The normal squamous 
cells did not show positivity in none of our cases. 
  Analyzing Cyclin D1  expression with the  T status there was 
no statistically significant difference between the expression patterns .The 
increasing T status did not show corresponding  over expression of 
Cyclin D1 .This may be explained by the fact that the  most of our 
patients present late  . 
  With regard to the nodal status again the over expression did 
not show any significant correlation. However 16 % of the cases with N2 
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did show over expression .Since the number of cases analysed is  small , a 
large study may throw  light on the correlation between Nodal disease 
and Cyclin D1. All the patients who have their nodes over expressing 
Cyclin D1 also had their primary over expressing Cyclin D1. 
                    With respect to the grade, of the 37 cases analysed there were 
16 cases of grade I tumors, 12 cases of grade II tumors and 9 cases of 
grade III tumors. None of the cases of grade I tumor over expressed 
cyclin D1 .Five  cases (41 % ) of grade II tumors over expressed Cyclin 
D1. However only 22% of grade III tumors over expressed Cyclin D1 . 
Even though this showed statistically significant p value, the grade 3 
tumors only 22 % over expressed which is paradoxical when compared to 
the grade 2 tumors. Since the number of cases studied was less and the 
grade of these tumors were analysed by different pathologists more 
standardization and inclusion of large numbers of cases may produce 
much more statistically significant values.  
  Even though the Cyclin D1 expression in recurrent tumors 
did not reach statistically significant value (p= 0.270), there is definite 
trend towards recurrence in tumors that over express Cyclin D1.a sudy 
with large number of patients in the future may show a significant 
correlation .  
  In some tumors there is a increased cyclin D1 RNA 
and/or protein without apparent gene amplification, suggesting that other 
cellular genes (such as the retinoblastoma gene) may impact on the 
protein expression of cyclin D1,57 although all the mechanisms have not 
yet been satisfactorily elucidated. .In breast cancers  it seems that cyclin 
D1 is more important in node positive,74 well differentiated, and 
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particularly lobular, varieties than other types of invasive breast cancer.91- 
93The role of cyclin D1 in ductal carcinoma in situ (DCIS) 98, high grade 
lesions 99 were more likely to show gene amplification but demonstrated 
lower percentages of nuclei expressing cyclin D1 protein than low grade 
lesions, which suggests that mechanisms other than gene amplification 
may be responsible for increased cyclin D1 protein. In this situation, 
assessment of cyclin D1 protein in combination with pRB may provide 
more useful information.100-102  The  over  expression of cyclin D  mRNA, 
determined by in situ hybridization, was able to distinguish DCIS from 
atypical ductal hyperplasia and other lesions associated with a low risk of 
progression to invasive carcinoma103. 
 35% to 64% of head and neck squamous carcinomas 106-111 
(squamous carcinomas in the oral cavity, nasopharynx, pharynx, 
hypopharynx, and larynx) show over expression of cyclin D1 and/or 
CCND1 amplification. Over expression of cyclin D1 in the initial surgical   
specimens   corresponds not only with more  frequent recurrence 109 but 
also with more advanced disease, lymph node involvement, and reduced 
overall survival. 107  110, over expression of cyclin D1 protein in resected 
material from head and neck squamous carcinomas was found to be an 
independent prognostic factor 111 In esophageal cancers,  results suggest 
that cyclin D1 may play an important role in carcinogenesis and that 
cyclin D1 over expression may be a useful prognostic factor 120 
Abnormalities of cyclin D1 are also common in both vulval and cervical 
squamous cell carcinomas. 135 At these sites, cyclin D1 appears to 
inactivate pRB in a similar manner to oncogenic human Papilloma virus 
genotypes. Thus, it seems that in vulval and cervical squamous 
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carcinomas, human papilloma virus proteins can circumvent cellular 
requirements for cyclin D1 136 or vice versa. 
 HPV which is the commonest etiological agent for carcinoma 
penis, especially in developing countries may result in gene expression 
abnormalities of cyclin d1 geneswhich may account for the over 
expression .More studies with correlation to hpv genome studies Cyclin 
D1 gene and other genes like Rb gene , p53 gene and their expression 
patterns are required to arrive at a definite conclusion .  
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                                 CONCLUSIONS  
CYCLIN D1 IS OVER EXPRESSED IN PENILE CANCERS 
 
HIGH GRADE SQUAMOUS CELL CARCINOMAS OVER 
EXPRESS CYCLIN D1, WHICH IS STATISTICALLY 
SIGNIFICANT 
 
EVEN THOUGH CYCLIN D1 EXPRESSION IN RECURRENT 
TUMORS IS NOT STATISTICALLY SIGNIFICANT, THERE IS A 
TREND TOWARDS OVER EXPRESSION IN RECURRENT 
TUMORS  
 
CYCLIN D1 EXPRESSION DOES NOT SHOW ANY 
CORRELATION WITH   ‘T’ STATUS AND ‘N’ STATUS. 
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FUTURE DIRECTIONS 
 
1. CYCLIN D1 MAY BE USED AS A PREDICTIVE AND 
PROGNOSTIC MARKER OF METASTASES , HOWEVER LARGE 
STUDY IS REQUIRED TO SHOW ITS DEFINITE SIGNIFICANCE  
2. MORE WORK IS NEEDED TO DETERMINE THE EXACT 
ASSOCIATION BETWEEN CYCLIN D1 AND HPV VIRUS. 
3. EXPRESSION OF CYCLIN D1 IN HIGH RISK NODE NEGATIVE 
PATIENTS MAY BE AN INDICATION FOR ELCTIVE NODAL 
DISSECTION. 
4. MORE WORK  NEEDS TO BE DONE  ON THE ROLE OF 
CYCLIN D1 IN PRECANCEROUS PENILE  LESIONS. 
5. EXPRESSION PATTERNS IN HIGH GRADE LESION MAY 
GUIDE THE ROLE OF  ADJUVANT THERAPY. 
6. GENE STUDIES ON THE EXPRESSION OF CCND1 GENES. 
7. CORRELATION BETWEEN  CYCLIN D1 AND HPV NEEDS TO 
BE IDENTIFIED. 
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